Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

“Taking these medications puts individuals at risk of everything from allergic reactions to uncontrolled blood sugar levels, ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...

Weight-loss jabs, known as GLP-1 receptor agonists, work by reducing food cravings. The NPA has previously urged patients to ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Britain’s pharmacists have called for tougher regulation of weight-loss drugs after reports showed some online sellers have set targets for clinicians to process more than 20 patients every hour.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...